ATE356200T1 - Kcnq kaliumkanäle und verfahren zur deren modulierung - Google Patents

Kcnq kaliumkanäle und verfahren zur deren modulierung

Info

Publication number
ATE356200T1
ATE356200T1 AT98932877T AT98932877T ATE356200T1 AT E356200 T1 ATE356200 T1 AT E356200T1 AT 98932877 T AT98932877 T AT 98932877T AT 98932877 T AT98932877 T AT 98932877T AT E356200 T1 ATE356200 T1 AT E356200T1
Authority
AT
Austria
Prior art keywords
kcnq2
proteins
kcnq3
potassium channels
disease
Prior art date
Application number
AT98932877T
Other languages
English (en)
Inventor
Michael A Blanar
Steven Dworetzky
Wen-Pin Yang
Paul C Levesque
Valentin K Gribkoff
Michael G Neubauer
Wayne A Little
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21998937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE356200(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE356200T1 publication Critical patent/ATE356200T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT98932877T 1997-08-12 1998-06-26 Kcnq kaliumkanäle und verfahren zur deren modulierung ATE356200T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5559997P 1997-08-12 1997-08-12

Publications (1)

Publication Number Publication Date
ATE356200T1 true ATE356200T1 (de) 2007-03-15

Family

ID=21998937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932877T ATE356200T1 (de) 1997-08-12 1998-06-26 Kcnq kaliumkanäle und verfahren zur deren modulierung

Country Status (10)

Country Link
US (4) US6403360B1 (de)
EP (1) EP1007638B1 (de)
JP (1) JP2001512673A (de)
AT (1) ATE356200T1 (de)
AU (1) AU731087B2 (de)
CA (1) CA2300985A1 (de)
DE (1) DE69837267T2 (de)
DK (1) DK1007638T3 (de)
ES (1) ES2281129T3 (de)
WO (1) WO1999007832A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837267T2 (de) * 1997-08-12 2007-10-31 Bristol-Myers Squibb Co. Kcnq kaliumkanäle und verfahren zur deren modulierung
WO1999021875A1 (en) * 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
CA2369822A1 (en) * 1999-04-14 2000-10-19 Merck & Co., Inc. Novel human voltage-gated potassium channel
US6649371B1 (en) * 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
EP1194447B1 (de) * 1999-06-11 2007-09-26 Neurosearch A/S Neue kalium-kanäle und dafür kodierende gene
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
EP1200086A4 (de) 1999-08-04 2009-05-27 Icagen Inc Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
DE10013732A1 (de) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh Das Kaliumkanalprotein KCNQ5, ein neuer Angriffspunkt bei Erkrankungen des zentralen Nervensystems und des Herz-Kreislauf-Systems
US7049137B2 (en) 2000-03-21 2006-05-23 Icagen, Inc. KCNQ5, a novel potassium channel
US6767736B2 (en) * 2000-04-03 2004-07-27 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
CA2410489A1 (en) * 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
CA2812948C (en) * 2010-09-28 2019-01-22 Nono Inc. Nd2 peptides and methods of treating neurological disease
FR3029113A1 (fr) * 2014-12-02 2016-06-03 Univ Paris-Sud Composes pour le traitement des maladies mitochondriales
US20230124616A1 (en) * 2020-03-06 2023-04-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09191882A (ja) 1996-01-16 1997-07-29 Japan Tobacco Inc ヒト新規ｋ＋チャネル蛋白質をコードするｄｎａおよびその断片
DE69837267T2 (de) * 1997-08-12 2007-10-31 Bristol-Myers Squibb Co. Kcnq kaliumkanäle und verfahren zur deren modulierung
WO1999021875A1 (en) * 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies

Also Published As

Publication number Publication date
AU731087B2 (en) 2001-03-22
EP1007638A4 (de) 2004-12-29
EP1007638A1 (de) 2000-06-14
US20020168724A1 (en) 2002-11-14
EP1007638B1 (de) 2007-03-07
US7041496B2 (en) 2006-05-09
US6403360B1 (en) 2002-06-11
JP2001512673A (ja) 2001-08-28
US20030044912A1 (en) 2003-03-06
DE69837267D1 (de) 2007-04-19
US7482431B2 (en) 2009-01-27
CA2300985A1 (en) 1999-02-18
US20070148692A1 (en) 2007-06-28
DE69837267T2 (de) 2007-10-31
US7262289B2 (en) 2007-08-28
ES2281129T3 (es) 2007-09-16
WO1999007832A1 (en) 1999-02-18
AU8266598A (en) 1999-03-01
DK1007638T3 (da) 2007-05-21

Similar Documents

Publication Publication Date Title
ATE356200T1 (de) Kcnq kaliumkanäle und verfahren zur deren modulierung
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE59807213D1 (de) 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
BR9500052A (pt) Mutante de gênero escherichia e processo para produção de ácido L-glutâmico por fermentação
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
DE59603216D1 (de) Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege
EA200200293A1 (ru) Бициклические аминокислоты в качестве фармацевтических агентов
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
WO2004058704A3 (en) Quinazolinones as potassium channel modulators
ATE299179T1 (de) Menschliche suppressor trna oligonukleotide und verfahren für deren verwendung
ATE259652T1 (de) Neuronale verwendungen des bmp-11
ATE391779T1 (de) Aus dem menschlichen gehirn stammender kcnq2 kaliumkanal
DE69527143T2 (de) Walzwerk zur herstellung von winkelstahl aus bandstahl
WO2001031008A3 (en) Human and rat fgf-20 genes and gene expression products
EA200001246A1 (ru) Карбамиды и карбаматы n-гетероциклических карбоновых кислот и изостер карбоновых кислот
DE69732772D1 (de) Enzymatisches verfahren zur stereoselektiven herstellung von therapeutischen amiden
DE69519799T2 (de) Verfahren zur herstellung von [s,s]-ethylendiamin-n,n'-dibernsteinsäure
ATE232721T1 (de) Verfahren zur vermehrung der produktion und zur verbesserung der qualität von sperma
DE69815476D1 (de) Verfahren zur Herstellung von Trehalose und Zuckeralkoholen
BR9704615A (pt) formononetina de metal alcalino e processo de estimulação micorrizal
EP1331265A3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
EP0891780A3 (de) Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
DE69812861D1 (de) Walzwerk zur herstellung von axialsymmetrischen teilen
DE69823191D1 (de) 1,2,3-thiadiazol-derivate, mittel zur kontrolle von pflanzenkrankheiten und methode zu seiner anwendung
Saftig et al. Downregulation of PS1 expression in neurons decreases beta-amyloid production: a biochemical link between the two major familial Alzheimer's disease genes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007638

Country of ref document: EP